Group 1 - The stock of Haooubo (688656) closed at 156.47 yuan on July 11, reaching the daily limit with a trading volume of 6.82 billion yuan and a turnover rate of 7.26% [2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 4.17 billion yuan, with a net purchase of 1.07 billion yuan [2] Group 2 - Among the top five buying departments, two were institutional special seats, with buying amounts of 83.68 million yuan and 50.80 million yuan respectively [3] - The Shanghai-Hong Kong Stock Connect was the second-largest buying department, with a purchase amount of 57.58 million yuan [3] - The leading selling department was Huatai Securities, with a selling amount of 50.61 million yuan [3]

Market Overview - The Shanghai Composite Index closed at 3510.18 points, up 0.01%, with a trading volume of 753.55 billion yuan [1] - The Shenzhen Component Index closed at 10696.10 points, up 0.61%, with a trading volume of 958.58 billion yuan [1] - The ChiNext Index closed at 2207.10 points, up 0.8%, with a trading volume of 460.02 billion yuan [1] - The STAR Market 50 Index closed at 994.45 points, up 1.48%, with a trading volume of 31.33 billion yuan [1] - The total trading volume of both markets reached 1712.13 billion yuan, an increase of 217.96 billion yuan compared to the previous trading day [1] Sector Performance - Strong sectors included securities, computers, steel, non-ferrous metals, pharmaceutical biology, national defense, home appliances, and machinery equipment [3] - Active concepts included rare earth permanent magnets, securities firms, digital currency, financial tax digitalization, small metals, and innovative drugs [3] - Weak sectors included banks, building materials, coal, textiles, education, and oil and petrochemicals [3] Individual Stock Performance - A total of 2769 stocks rose, while 2135 stocks fell, with 239 stocks remaining flat [3] - 68 stocks hit the daily limit up, while 14 stocks hit the daily limit down [3] - Notable stocks with consecutive limit ups included Guotou Zhonglu and Sifang New Materials, both with 5 consecutive limit ups [5] Fund Flow Analysis - The net outflow of main funds in the two markets was 14.038 billion yuan, with the ChiNext experiencing a net outflow of 3.261 billion yuan [6] - The computer sector saw the highest net inflow of main funds, amounting to 3.691 billion yuan [6] - A total of 1985 stocks received net inflows, with 73 stocks receiving over 1 billion yuan in net inflows [10] Institutional Activity - Institutions had a net buy of approximately 473 million yuan, with the highest net buy in Haooubo at about 134 million yuan [17] - The stocks with the highest net outflows included Tianfu Communication, with a net outflow of 611 million yuan [13]

Group 1 - The stock of Haobor reached a daily limit increase of 20%, with a trading volume of 682 million yuan and a turnover rate of 7.26% [1] - Data from the post-market dragon and tiger list indicates that the Shanghai Stock Connect dedicated seat purchased 57.58 million yuan [1] - Two institutional dedicated seats net bought 134 million yuan [1]

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

证券代码：688656 证券简称：浩欧博 公告编号：2025-039 江苏浩欧博生物医药股份有限公司 2023 年限制性股票激励计划首次授予部分第二类激励 对象第一个归属期归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 421,412股。 本次股票上市流通总数为421,412股。 本次股票上市流通日期为2025 年 7 月 4 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，江苏浩欧博生物医药股份有限公司（以下简称 "公司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券 变更登记证明》，公司完成了 2023 年限制性股票激励计划首次授予部分第二类激 励对象第一个归属期的股份归属登记工作。现将有关情况公告如下： 3、2023 年 9 月 15 日至 2023 年 9 月 24 日，公司对本激励计划首次授予部分 激励对象的姓名和职务在公司内部进行了公示。 ...

Core Insights - The total margin financing balance on the STAR Market increased by 1.26 billion yuan compared to the previous trading day, while the margin short selling balance decreased by 5.71 million yuan [1] - As of June 26, the total margin balance on the STAR Market reached 157.09 billion yuan, marking a continuous increase for four consecutive trading days [1] - The highest margin financing balance was recorded for SMIC at 7.17 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.52 billion yuan and 3.50 billion yuan respectively [1] Margin Financing Summary - 359 stocks on the STAR Market saw an increase in margin financing balance, while 225 stocks experienced a decrease [1] - Notable increases in margin financing balance were observed for Haooubo (29.57%), Huachuang Technology (28.45%), and Beiqing Song (24.44%) [1][2] - The largest decreases were seen in Delong Laser (-12.32%), Changying Tong (-10.57%), and Sitwei (-10.27%) [1][2] Margin Short Selling Summary - The highest margin short selling balance was for Haiguang Information at 1.8 million yuan, followed closely by SMIC and Cambrian at 1.6 million yuan and 1.6 million yuan respectively [2] - 93 stocks on the STAR Market reported an increase in margin short selling balance, while 176 stocks saw a decrease [2] - Significant increases in margin short selling balance were noted for Maixinlin (96.41%), Tianzhun Technology (69.57%), and Anheng Information (62.26%) [2][3] - The largest decreases were recorded for Huaxing Yuanchuang (-51.21%), Huazhu Gaoke (-50.61%), and Chipengwei (-46.64%) [2][3]

Market Performance - The Sci-Tech Innovation Board (STAR Market) index fell by 0.57%, closing at 989.97 points, with a total trading volume of 3.251 billion shares and a turnover of 114.114 billion yuan, resulting in a weighted average turnover rate of 1.84% [1] - Among the tradable stocks on the STAR Market, 149 stocks closed higher, with 5 stocks rising over 10%, including Xinan Century and Huachuang Technology, which hit the daily limit [1] - A total of 429 stocks closed lower, with 1 stock declining over 10% [1] Turnover Rate Analysis - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 19 stocks had rates between 10% and 20%, and 62 stocks had rates between 5% and 10% [1] - The highest turnover rate was for Huasheng Lithium Battery at 23.52%, closing up by 6.09%, with a transaction amount of 512 million yuan [1] - Other notable stocks with high turnover rates include Xinyu Ren at 22.71% (closing down 0.63%) and Shengke Nano at 19.29% [1] Sector Performance - Among stocks with turnover rates exceeding 5%, 46 stocks rose, with the highest increases from Xinan Century (20.02%), Huachuang Technology (19.99%), and Nanmo Biology (10.53%) [2] - The sectors with the most stocks exceeding a 5% turnover rate were electronics (20 stocks), followed by computer and defense industries with 17 and 11 stocks, respectively [2] Capital Flow - In terms of capital flow, 44 stocks with high turnover rates saw net inflows from main funds, with significant inflows into Xinan Century (78.4476 million yuan), Huachuang Technology (62.4199 million yuan), and Haooubo (62.1777 million yuan) [2] - Conversely, stocks with the largest net outflows included Guokai Military Industry (134 million yuan), Liyuanheng (127 million yuan), and Yingshi Innovation (124 million yuan) [2] Leverage Fund Movements - A total of 46 stocks with high turnover rates received net purchases from leveraged funds, with notable increases in financing balances for Juxin Technology (128 million yuan), Yingshi Innovation (84.5376 million yuan), and Huafeng Technology (70.1917 million yuan) [2] - Stocks with the largest decreases in financing balances included Zhongwu Drone (69.032 million yuan), Lais Information (49.6791 million yuan), and Changyang Technology (43.9972 million yuan) [2]

Core Viewpoint - The medical device sector is experiencing a significant rise, with stocks such as Haooubo hitting the daily limit of 20% increase, driven by regulatory support for high-end medical device innovation [1] Group 1: Stock Performance - Haooubo's stock surged to a 20% limit increase in the afternoon trading session [1] - Other companies like Nanwei Co., Kangwei Century, Kangzhong Medical, and Aohua Endoscopy saw increases of over 5% [1] - Additional stocks such as Libang Instruments, Chutian Technology, and Baolait also experienced upward movement [1] Group 2: Regulatory Support - The National Medical Products Administration has approved measures to optimize lifecycle regulation to support the innovation of high-end medical devices [1] - New measures aimed at fostering high-end medical device innovation are expected to be introduced [1]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Composite Index (000680) decreased by 1.08% as of June 13, 2025, with mixed performance among constituent stocks [3] - Jin Chengzi (688291) led the gains with an increase of 20.01%, while Hao Oubo (688656) experienced the largest decline at 9.33% [3] - The Huaxia Sci-Tech Innovation Index ETF (589000) fell by 1.16%, with a latest price of 0.94 yuan and a turnover rate of 4.48%, totaling a transaction volume of 1.03 billion yuan [3] Group 2 - According to Zheshang Securities, global enterprise software and IT service spending is projected to reach $1.25 trillion and $1.73 trillion by 2025, reflecting year-on-year growth of 14.2% and 9.0% respectively [4] - The growth is primarily driven by the deep integration of AI in various business scenarios, including management, customer service, marketing, and sales, as well as its role in the digital transformation of traditional vertical industries [4] - The artificial intelligence sector is highlighted as having technological leadership, broad market prospects, clear commercialization pathways, and high profit potential, making it a key investment focus [4]